Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Immunogenicity of a novel inactivated canine adenovirus type 2 variant vaccine for dogs

  • Dong-Kun Yang (Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs) ;
  • Sangjin Ahn (Section of Wildlife Internal Medicine, College of Veterinary Medicine, Kangwon National University) ;
  • Hye Jeong Lee (Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs) ;
  • Minuk Kim (Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs) ;
  • Jong-Taek Kim (Section of Wildlife Internal Medicine, College of Veterinary Medicine, Kangwon National University) ;
  • Ju-Yeon Lee (Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs) ;
  • Yun Sang Cho (Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs)
  • Received : 2024.05.31
  • Accepted : 2024.06.21
  • Published : 2024.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The immunogenicity of vaccines containing the canine adenovirus (CAdV) type 2 (CAdV-2) variant has not yet been reported. We prepared a novel inactivated CAdV-2 variant vaccine using the CAV2232-41 strain, and evaluated its safety and immunogenicity in raccoon dogs. Materials and Methods: The growth kinetics of CAV2232-41 were determined using Madin-Darby Canine Kidney (MDCK) cells. The nucleotide sequences of CAV2232 and CAV2232-41 were determined by next-generation sequencing. To generate the CAdV-2 variant vaccine, CAV2232-41 propagated in the MDCK cells was inactivated with 0.1% formaldehyde. Two vaccines were prepared by blending inactivated CAV2232-41 with Cabopol and Rehydragel adjuvants. Safety and immunogenicity of the CAV2232C and CAV2232R vaccines were evaluated in guinea pigs. Safety and immunogenicity of the CAV2232C vaccine were also evaluated in raccoon dogs. The virus neutralizing antibody (VNA) titer against CAV2232-41 was measured in sera collected from immunized guinea pigs and raccoon dogs. Results: CAV2232-41 showed the highest viral titer on days 4-6 post-inoculation and had a deletion in the E3 gene, which was confirmed as a CAdV-2 variant. Guinea pigs inoculated with CAV2232C showed slightly higher VNA titers than those inoculated with CAV2232R 2 weeks after booster vaccination. Raccoon dogs immunized with the CAV2232C vaccine developed high mean VNA titers, while non-vaccinated raccoon dogs were antibody-negative. Conclusion: The CAV2232C vaccine is safe and induces a protective VNA titer in raccoon dogs.

Keywords

Acknowledgement

This study was supported financially by a grant (B-1543083-2023-24-01) from the Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA), Republic of Korea.

References

  1. Decaro N, Martella V, Buonavoglia C. Canine adenoviruses and herpesvirus. Vet Clin North Am Small Anim Pract 2008;38:799-814. https://doi.org/10.1016/j.cvsm.2008.02.006
  2. Zhu Y, Xu J, Lian S, et al. Difference analysis between canine adenovirus types 1 and 2. Front Cell Infect Microbiol 2022;12:854876.
  3. Hu RL, Huang G, Qiu W, et al. Detection and differentiation of CAV-1 and CAV-2 by polymerase chain reaction. Vet Res Commun 2001;25:77-84. https://doi.org/10.1023/A:1006417203856
  4. Buonavoglia C, Martella V. Canine respiratory viruses. Vet Res 2007;38:355-73. https://doi.org/10.1051/vetres:2006058
  5. Chvala S, Benetka V, Mostl K, et al. Simultaneous canine distemper virus, canine adenovirus type 2, and Mycoplasma cynos infection in a dog with pneumonia. Vet Pathol 2007;44:508-12. https://doi.org/10.1354/vp.44-4-508
  6. Viitanen SJ, Lappalainen A, Rajamaki MM. Co-infections with respiratory viruses in dogs with bacterial pneumonia. J Vet Intern Med 2015;29:544-51. https://doi.org/10.1111/jvim.12553
  7. Kim YJ, Lee SY, Kim YS, et al. Genetic characteristics of canine adenovirus type 2 detected in wild raccoon dogs (Nyctereutes procyonoides) in Korea (2017-2020). Vet Sci 2022;9:591.
  8. Park NY, Lee MC, Kurkure NV, et al. Canine adenovirus type 1 infection of a Eurasian river otter (Lutra lutra). Vet Pathol 2007;44:536-9. https://doi.org/10.1354/vp.44-4-536
  9. Choi JW, Lee HK, Kim SH, et al. Canine adenovirus type 1 in a fennec fox (Vulpes zerda). J Zoo Wildl Med 2014;45:947-50. https://doi.org/10.1638/2013-0286.1
  10. Yang DK, Kim HH, Yoon SS, et al. Isolation and identification of canine adenovirus type 2 from a naturally infected dog in Korea. Korean J Vet Res 2018;58:177-82. https://doi.org/10.14405/kjvr.2018.58.4.177
  11. Duque-Valencia J, Sarute N, Olarte-Castillo XA, et al. Evolution and interspecies transmission of canine distemper virus: an outlook of the diverse evolutionary landscapes of a multi-host virus. Viruses 2019;11:582.
  12. Fu Y, Sun J, Lian S, et al. Immunogenicity of an inactivated canine adenovirus type 1 vaccine for foxes. Front Vet Sci 2022;9:678671.
  13. Yang DK, Kim HH, Yoon SS, et al. Incidence and sero-survey of canine adenovirus type 2 in various animal species. J Bacteriol Virol 2018;48:102-8. https://doi.org/10.4167/jbv.2018.48.3.102
  14. Yang DK, Kim HH, Yoo JY, et al. Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs. Clin Exp Vaccine Res 2020;9:40-7. https://doi.org/10.7774/cevr.2020.9.1.40
  15. Benetka V, Weissenbock H, Kudielka I, et al. Canine adenovirus type 2 infection in four puppies with neurological signs. Vet Rec 2006;158:91-4. https://doi.org/10.1136/vr.158.3.91
  16. Chander V, Sharma GK, Bhatt M, et al. Isolation and genetic characterization of canine adenovirus type 2 from a domestic dog showing neurological symptoms. Braz J Microbiol 2021;52:2521-8. https://doi.org/10.1007/s42770-021-00540-0
  17. Goldstein T, Colegrove KM, Hanson M, et al. Isolation of a novel adenovirus from California sea lions Zalophus californianus. Dis Aquat Organ 2011;94:243-8. https://doi.org/10.3354/dao02321
  18. Takamura K, Ajiki M, Hiramatsu K, et al. Isolation and properties of adenovirus from canine respiratory tract. Nihon Juigaku Zasshi 1982;44:355-7. https://doi.org/10.1292/jvms1939.44.355
  19. Kalinowski M, Adaszek L, Miloszowska P, et al. Molecular analysis of a fragment of gene E1B 19K of canine adenovirus 2 (CAV-2) isolated from dogs with symptoms of cough. Pol J Vet Sci 2012;15:425-30. https://doi.org/10.2478/v10181-012-0066-7
  20. Del Rio D, Beucher B, Lavigne M, et al. CAV-2 vector development and gene transfer in the central and peripheral nervous systems. Front Mol Neurosci 2019;12:71.
  21. Gerdts V. Adjuvants for veterinary vaccines: types and modes of action. Berl Munch Tierarztl Wochenschr 2015;128:456-63.
  22. Gelfi J, Pappalardo M, Claverys C, et al. Safety and efficacy of an inactivated Carbopol-adjuvanted goose haemorrhagic polyomavirus vaccine for domestic geese. Avian Pathol 2010;39:111-6. https://doi.org/10.1080/03079451003604647
  23. Zhang J, Wang M, Zhou N, et al. Evaluation of carbopol as an adjuvant on the effectiveness of progressive atrophic rhinitis vaccine. Vaccine 2018;36:4477-84. https://doi.org/10.1016/j.vaccine.2018.06.023
  24. Banse HE, McKenzie EC, Nelson S, et al. Assessment of serum antibody titers against canine distemper virus, canine adenovirus type II, and canine parvovirus in Alaskan sled dogs before and after a long-distance race. J Am Vet Med Assoc 2008;232:1669-73. https://doi.org/10.2460/javma.232.11.1669